Please login to the form below

Not currently logged in

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

Merck & Co headquartersMerck & Co hit a setback in its hepatitis C ambitions with the decision by the US FDA to rescind the 'breakthrough' therapy status for a new oral drug.

The company said in its financial statement for 2014 that its combination of grazoprevir and elbasvir no longer qualifies for the designation due to availability of recently approved hepatitis C medicines.

The FDA reserves its breakthrough status for medicines that demonstrate substantial improvement over available therapies in early clinical trials and is intended to speed up the development and review process for new drugs.

By having the status rescinded for grazoprevir/elbasvir rescinded Merck misses out on several benefits during the review process, including intensive guidance on an efficient drug development programme, organisational commitment involving senior managers and all the features of the FDA's 'fast track' programme.

Merck said it “expects to discuss this matter with the FDA” and still intends to go through with the marketing application for grazoprevir/elbasvir.

The hepatitis C market has seen a number of major new oral treatments launched in the past couple of years that offer 90%+ cure rates and more convenient regimens than previous therapies.

These have been led by Gilead Sciences' Sovaldi (sofosbuvir), which had sales of more than $10bn for 2014 after being launched at the end of 2013.

The drug has since been joined by Gilead's Harvoni, which combines Sovaldi with ledipasvir and has been a major success in its own right with sales of $2bn in 2014 after launching towards the end of the year.

Other new hepatitis C treatments include AbbVie's Viekira Pak and Janssen's Olysio (simeprevir).

Article by
Thomas Meek

5th February 2015

From: Sales, Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...